Arena Pharma appoints three new members to board
Jayson Dallas has successfully overseen multiple product launches and has led numerous commercial organizations through periods of rapid growth over the course of his more than 20 years in the pharmaceutical industry.
Dr. Dallas currently serves as the Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceuticals, a biopharmaceutical company developing novel products for rare and ultra-rare diseases.
Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche UK. Prior to this, he held senior positions at Genentech, Novartis, Pharmacia and Roche.
He earned his medical degree from the University of the Witwatersrand, Johannesburg, South Africa and an MBA from Ashridge Business School in the United Kingdom.
Oliver Fetzer has extensive experience in successful clinical development, deal transactions and biopharmaceuticals leadership over his more than 20 years in the industry.
He is currently the Chief Executive Officer at Synthetic Genomics, a global leader in the field of synthetic biology and synthetic genomics.
Dr. Fetzer previously served as the Chief Executive Officer at Cerulean Pharma and in a variety of senior management positions at Cubist Pharmaceuticals.
He began his career and assumed various positions of increasing responsibility at the Boston Consulting Group (BCG). He serves on the board of Tecan Group AG.
Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.
Garry A. Neil has over two decades of biopharmaceutical experience with an emphasis on drug development and regulatory strategy. Dr. Neil currently serves as Chief Scientific Officer of Aevi Genomic Medicine, a biotechnology company focused on genomic medicine.
Previously, he held a number of senior positions in the pharmaceutical industry, academia and venture capital, including positions at Johnson & Johnson, Merck KGaA/EMD Pharmaceuticals, AstraZeneca and Astra Merck.
He is the Founding Chairman of the pharmaceutical industry R&D consortium, TransCelerate Biopharma, and remains on its board.
He also serves on the boards of Reagan Udall Foundation and GTx Pharmaceuticals.
Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine.
He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto and completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic.
In addition, current directors Harry F. Hixson, Jr., Ph.D. and Donald D. Belcher will be retiring from the Board at the annual meeting. ■
What to read next
LATEST MOVES FROM California
- NuVasive appoints Rajesh J. Asarpota as CFO
- Sanmina appoints David Anderson as CFO
- RPX Corporation appoints Marty Roberts to board
- Pfenex appoints Evert Schimmelpennink as CEO
- Aqua Metals appoints Mark Weinswig as CFO
More inside POST
Tyson Foods Q3 profit down Earnings